Schedule 13G ownership disclosure

4D Molecular Therapeutics Inc

Common Stock · CUSIP: 35104E100

Event date: 2025-03-31

Filing-level shares
3,615,316
Percent of class
7.8%
  • BlackRock, Inc.

    Shares: 3,615,316 · Class: 7.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001576419-25-000599
Form type
SCHEDULE 13G/A
Filer
4D Molecular Therapeutics, Inc.
CIK
CIK 1650648
Filed
Apr 17, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub